The Evidence Layer for Scientific AI

 Quick Answer Copied

 Long Answer

What the paper establishes

The study closes a real diagnostic gap: despite flow cytometry's advantages for MPO lineage assignment, no de facto standard definition of MPO positivity existed. Using the standardised EuroFlow Acute Leukaemia Orientation Tube (MPO:FITC, clone MPO-7) and 1,734 AL cases, the authors systematically optimised both the positivity threshold (780 FIU, lymphocyte-based) and the positivity cut-off (≥20% of AL cells), achieving near-optimal AUCs for both ALL-vs-monocyte (0.993) and WHO-NEG-vs-WHO-POS AML (0.946) discrimination.Threshold and cut-off optimisation details

Cohort composition and validation design

The training cohort (DCOG 2010–2015; Erasmus MC 2010–2018: 527 BCP-ALL, 134 T-ALL, 519 AML) and independent five-centre validation cohort (315 BCP-ALL, 56 T-ALL, 154 AML, 29 MPAL) showed near-identical results, supporting assay stability over time, across centres and across two cytometrists.Multicentre cohort and stability data

Critical appraisal

• Reference standard gap: Cytomorphological MPO status was not used as ground truth, so the definition is internally optimised against control pairs (ALL vs monocytes; WHO-NEG vs WHO-POS AML) rather than externally validated against an independent gold standard — a limitation the authors openly discuss.Absence of cytomorphological gold standard
• Circular control selection: WHO-NEG/WHO-POS pairs were not fully MPO-negative/positive (two MPO-positive acute megakaryocytic cases), though temporary exclusion barely changed thresholds — reported robustness evidence.Control impurity and robustness checks
• Conflict of interest: Five authors hold EuroFlow patents licensed to Cytognos and BD Biosciences with royalty payments — a structural incentive favouring the EuroFlow ALOT platform that readers should weigh when assessing the claim that the approach is the missing standard.Disclosed patent and royalty conflicts
• MPAL reclassification: Six of 29 MPAL cases became MPO-negative under the new definition and were formally reclassified per WHO criteria — clinically consequential, showing the definition changes diagnoses, not just labels.MPAL reclassification impact
• Information loss: The binary classifier discards continuous MPO.PPC data; the authors rightly recommend reporting both.

Overall: a methodologically careful, transparently confessional standardisation study of immediate practical utility for AL diagnostics, whose generality beyond EuroFlow-standardised platforms remains asserted rather than demonstrated. What would change this verdict: an independent multicentre comparison against cytomorphological reference MPO status showing superior or equivalent misclassification rates.

 BGPT Paper Review

Study Novelty

First de facto standard definition of MPO positivity for the EuroFlow ALOT; prior studies (e.g. 10–13% cut-offs) were smaller and non-standardised, but the concept of MPO flow cytometry thresholds is not new.

Scientific Quality

Large multicentre cohort, stability checks, continuous threshold evaluation, and transparent limitation discussion; main weaknesses are absent cytomorphological reference, imperfect control purity, and disclosed patent/royalty conflicts for five authors.

Study Generality

MPO positivity definition directly affects WHO lineage assignment and MPAL classification in acute leukaemia broadly, though the specific 780 FIU value is platform/protocol-dependent.

Study Usefulness

Provides an immediately adoptable, reproducible MPO positivity rule that completes the ALOT as a fully standardised MPO status assay, with direct clinical classification impact (six MPAL reclassifications).

Study Reproducibility

EuroFlow protocols are publicly available, thresholds/cut-offs fully specified, stability data in supplementary material; but data and software sharing is not explicitly stated.

Explanatory Depth

Deep empirical characterisation of MPO expression heterogeneity (skewness ~76%, subclones ~5%) and information loss from binarisation, though no mechanistic account of MPO-positive ALL biology.